Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-218-5p agomir
- Development stage
- Preclinical
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intracerebral
01
Overview
miR-218-5p agomir is a chemically modified, double-stranded microRNA (miRNA) mimic designed to enhance the activity of endogenous miR-218-5p. In preclinical research focused on Parkinson's disease, it has been shown to regulate microglia-mediated neuroinflammation and exert a protective effect on dopaminergic neurons. The mechanism of action involves the direct targeting and downregulation of DEAD-box helicase 41 (DDX41), which subsequently inhibits the Type I interferon (IFN-I) response pathway. By suppressing the expression of IFN-I related genes such as Irf7, Ddx60, and Nlrc5, the agomir reduces the induction of inflammatory cytokines and alleviates motor dysfunction in animal models.
- Other names
- microRNA-218-5p agomirmicroRNA218-5p agomirmicroRNA 218-5p agomirmmu-miR-218-5p agomirmmu-miR218-5p agomirmmu-miR 218-5p agomir
02
Targets
A disintegrin and metalloproteinase with thrombospondin motifs 5 mRNA 3′ untranslated regionDDX41
Beyond the preview
Go deeper on miR-218-5p agomir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-218-5p agomir.